96 Tests PN: B112485

Components:

45x Ab-conjugated beads (S4P3 - Human GROα Ab-bead). PN: B112485A. One vial containing 100 µL of anti-Human GROα conjugated to AimPlex Bead S4P3.

25x Biotin-detection Ab (Human GROα Biotin-dAb). PN: B112485B. One vial containing 100 µL of biotinylated anti-Human GROα.

Lyophilized Standard Mix-Human Group 7, Panel A, 8-Plex. PN: HG71008. One vial containing lyophilized recombinant Eotaxin-3, GCP-2, GROα, HCC-1, HCC-4, I-309, MCP-2, and MPIF-1. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human CXCL1/MGSA/GROα. Can be multiplexed with other analytes in Human Group 7.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < `10 pg/mL

  • ULOQ: > 2,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 7: Negligible

  • Sample volume: 15 µL/test

Description:

CXCL1 (chemokine C-X-C motif ligand 1) is a small cytokine belonging to the CXC chemokine family that was previously called GRO1 oncogene, GROα, KC, neutrophil-activating protein 3 (NAP-3) and melanoma growth stimulating activity, alpha (MSGA-α).  CXCL1 is secreted by human melanoma cells, has mitogenic properties and is implicated in melanoma pathogenesis. CXCL1 is expressed by macrophages, neutrophils and epithelial cells, and has neutrophil chemoattractant activity. CXCL1 plays a role in spinal cord development by inhibiting the migration of oligodendrocyte precursors and is involved in the processes of angiogenesis, inflammation, wound healing, and tumorigenesis. An initial study in mice showed evidence that CXCL1 decreased the severity of multiple sclerosis and may offer a neuro-protective function. Diseases associated with CXCL1 include chronic granulomatous disease and melanoma.

References:

  1. Haskill S, Peace A, Morris J, Sporn SA, Anisowicz A, Lee SW, Smith T, Martin G, Ralph P, Sager R (October 1990). "Identification of three related human GRO genes encoding cytokine functions". Proc. Natl. Acad. Sci. U.S.A. 87 (19): 7732–6. doi:10.1073/pnas.87.19.7732. PMC 54822. PMID 2217207.

  2. Anisowicz A, Bardwell L, Sager R (October 1987). "Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells". Proc. Natl. Acad. Sci. U.S.A. 84 (20): 7188–92. doi:10.1073/pnas.84.20.7188. PMC 299255. PMID 2890161.

  3. Richmond A, Thomas HG (February 1988). "Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution". J. Cell. Biochem. 36 (2): 185–98. doi:10.1002/jcb.240360209. PMID 3356754

  4. Owen JD, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R, Richmond A (September 1997). "Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins". Int. J. Cancer 73 (1): 94–103. doi:10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5. PMID 9334815.